Answers are grounded in this paper and cite their sources.
Background Chikungunya arthritis comprises overlapping pain-dominant, periarticular, inflammatory, and rheumatoid arthritis (RA)-like clinical phenotypes. Symptom duration alone does not capture this heterogeneity. Scope This narrative review evaluates virological assays, antiviral and autoimmune serology, inflammatory mediators, imaging, and clinical outcomes. Human observations are distinguished from animal and cell-based mechanisms. Findings Most biomarker evidence is exploratory. Associations with concurrent symptoms must be distinguished from prediction of later disease and from prediction of differential treatment benefit. Small samples, heterogeneous assays and sampling times, treatment exposure, and limited external validation restrict interpretation. Neither persistent antiviral antibodies nor an isolated cytokine elevation identifies a validated treatment-responsive subgroup. Tissue viral RNA or antigen does not establish productive infection or a causal explanation for persistent symptoms. Clinical phenotypes are observable states; proposed mechanistic endotypes remain unvalidated. Implications Current assessment should integrate disease phase, objective inflammation, functional burden, comorbidity, and alternative diagnoses. Evidence for methotrexate is limited by combination regimens, uncontrolled observations, and small comparative trials. Antivirals, neutralizing antibodies, and pathway-targeted immunomodulators remain investigational for CHIKV arthritis. Personalized treatment is a research agenda requiring longitudinal cohorts and prospective biomarker-by-treatment interaction trials, rather than a currently available biomarker-directed strategy.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: